Patents Represented by Attorney, Agent or Law Firm Mary E. McCarthy
  • Patent number: 6664259
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: December 16, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Patent number: 6660751
    Abstract: The invention relates to novel sulfonamide compounds having 5-HT7 receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: December 9, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Peter John Lovell
  • Patent number: 6653310
    Abstract: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: November 25, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael R. Palovich, Katherine L. Widdowson, Hong Nie
  • Patent number: 6653347
    Abstract: This invention relates to the novel use of diphenyl sulfamido in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: November 25, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael R. Palovich, Joseph Weinstock, Katherine L. Widdowson
  • Patent number: 6645960
    Abstract: A compound of general formula (I) and physiologically acceptable salts wherein R represents phthalidyl, (2-oxo-5-methyl-1,3-diox-olen-4-yl)methyl or the group CHR4 OCO(O)pR5 wherein R4 is hydrogen or C1-4 alcyl, p is zero or I, R5 is C1-6 alkly, C5-8 cycloalyl (optionally substituted by C1-3 alkyl or carboxyl), C1-4 alkyl substituted by C1-3 alkoxy or carboxy), C1-4 alkyl substituted by one or more groups selected from amino, (C1-4 alkylamino di(C1-4 alkyl)amino or carboxyl, phenyl (optionally substituted by carboxyl or aminoalkyl, C1-4 alkylaminoalkyl or di(C1-4 alkyl)aminoalcyl, or R5 is a 5-8 membered heterocyclic group containing 1 or 2 heteroatoms selected from oxygen or nitrogen, processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: November 11, 2003
    Assignee: Glaxo Wellcome S.A.
    Inventors: Jose Maria Fiandor, Sophie Huss
  • Patent number: 6632947
    Abstract: A process for preparing a compound of formula (I, I) or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, wherein: J represents O or S; T represents a substituted or unsubstituted aryl group and T1 is O or S; which process comprises reducing a compound of formula (II, II) or a tautomeric form thereof or a salt thereof or a solvate thereof, wherein T and T1 are as defined in relation to formula (I), with a complex hydride reducing agent or a source of a complex hydride reducing agent; and thereafter, as required, preparing a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate of the compound of formula (I) or a tautomeric form thereof.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: October 14, 2003
    Assignee: SmithKline Beecham plc
    Inventors: Robert Gordon Giles, Norman John Lewis, Stephen Moore, Colin Ripley Pool, John Kirby Quick, Michael Urquhart
  • Patent number: 6630498
    Abstract: This invention relates to (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid arginyl charge-neutralization-complex, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: October 7, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Manga R Gudipati, John M Jushchyshyn, Nageswara R Palepu, Gopadi M Venkatesh
  • Patent number: 6627661
    Abstract: Methods for treating ADHD, comprising administering 5-HT6 antagonists to subjects having ADHD, are disclosed.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: September 30, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Charles Alan Reavill, Carol Routledge
  • Patent number: 6617124
    Abstract: Coumarin derivatives as substrates for cytochrome P450 enzyme.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: September 9, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Stephen Edward Clarke
  • Patent number: 6608077
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: August 19, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Patent number: 6608059
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: August 19, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert A. Daines, Israil Pendrak
  • Patent number: 6602882
    Abstract: Piperidine derivatives and pharmaceutical derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: August 5, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: David Thomas Davies, Roger Edward Markwell, Neil David Pearson, Andrew Kenneth Takle
  • Patent number: 6599904
    Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: July 29, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Francis David King, Paul Adrian Wyman
  • Patent number: 6583294
    Abstract: A process for the preparation of methyl 2-(3-chloropropoxy)-indole-3-carboxylate, which comprises reacting a 3-chloro-3-carboxylate indole compound with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: June 24, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Michael Fedouloff, John Bryce Strachan
  • Patent number: 6576643
    Abstract: Compounds of the formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: June 10, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: William E. Bondinell, William H. Miller, Dirk Heerding, James M. Samanen
  • Patent number: 6570037
    Abstract: A compound of formula (I): or a salt thereof, or a solvate thereof, wherein Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen; A represents a C1-4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C1-6 alkyl groups; R1 represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of of the group of R2, R3 and R4 represents nitro the remaining members of the group of R2, R3 and R4 represent hydrogen; X represents a —CO—NH— moiety; and Z represents C2-4 n-alkylene group wherein each carbon is optionally substituted 1 or 2 C1-6 alkyl groups; a process for preparing such compounds, pharmaceutical compositions comprising such compounds and the use of such compo
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: May 27, 2003
    Assignee: SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Guy Marguerite Marie Gerard Nadler, Michel Jean Roger Martin
  • Patent number: 6566373
    Abstract: The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: May 20, 2003
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Andrew D Gribble, Ashley Edward Fenwick, Robert W Marquis, Daniel F Veber, Jason Witherington
  • Patent number: 6566387
    Abstract: The invention relates to the use of guanidine compounds in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: May 20, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael R. Palovich, Katherine L. Widdowson
  • Patent number: 6558699
    Abstract: This invention relates to high drug load granulation of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid in the anhydrous form, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: May 6, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Gopadi M. Venkatesh
  • Patent number: 6559172
    Abstract: Novel disubstituted imidazoles are disclosed which are useful in the treatment of bacterial infections, particularly through the inhibition of FAB I.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: May 6, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Dirk Heerding, Kenneth A. Newlander